FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2076656264> ?p ?o ?g. }

• W2076656264 endingPage "1286" @default.
• W2076656264 startingPage "1275" @default.
• W2076656264 abstract "This study evaluated the effects of an mTOR inhibitor everolimus alone or in combination with letrozole on MCF-7/Aro (MCF-7 cells stably transfected with CYP19) in vitro and in vivo. In vitro studies, full-length CYP19 (aromatase) was cloned in a plasmid transfer vector pH ß-Aro and then transfected into MCF-7 stem cells which were ESA(+)CD44(+)CD24(-/low) sorted by flow cytometry. MTT assays were used to quantify the inhibitory effect of the drugs on MCF-7/Aro stem cells (SCs) and non-stem cells (NSCs). Apoptosis and the cell cycle distributions of stem cells were examined by flow cytometry. The tumorigenicity of stem cells after treatment was investigated by soft agar colony formation assays. In vivo studies, the BALB/c mice were injected with MCF-7/Aro SCs, and the different treatments were administered. After necropsy, the expression of KI67, CD31, AKT1, phospho-AKT (Thr308), and mTOR was analyzed by immunohistochemistry. In vitro, compared with MCF-7/Aro NSCs, there were greater resistance to the standard treatment doses of letrozole and everolimus in MCF-7/Aro SCs (17- and 15-fold, respectively). Treatment with everolimus or letrozole resulted in growth inhibition of SCs in a dose-dependent manner. Compared with single-agent therapy, the combination of everolimus with letrozole was more effective in the inhibition of cell growth (P < 0.001) and tumorigenicity (P < 0.01). In addition, an increase in G1 cell cycle arrest and increases in early apoptosis were observed in the combination treatment group compared with either single-agent group. In vivo, the xenograft tumor sizes were significantly decreased in everolimus alone group compared to control group, and everolimus plus letrozole therapy was much more effective compared with either single agent alone (P < 0.01). Compared with everolimus alone, the combination of everolimus and letrozole reduced the expression of KI67, mTOR, and phospho-AKT (Thr308; P < 0.01). Everolimus has effective inhibition on aromatase-overexpressing stem cell in vitro and in vivo. The combination everolimus and letrozole could be more effective than either drug alone." @default.
• W2076656264 created "2016-06-24" @default.
• W2076656264 creator A5021293751 @default.
• W2076656264 creator A5033919927 @default.
• W2076656264 creator A5047855118 @default.
• W2076656264 creator A5055174519 @default.
• W2076656264 creator A5068812571 @default.
• W2076656264 creator A5077322975 @default.
• W2076656264 date "2013-09-08" @default.
• W2076656264 modified "2023-09-23" @default.
• W2076656264 title "Everolimus in combination with letrozole inhibit human breast cancer MCF-7/Aro stem cells via PI3K/mTOR pathway: an experimental study" @default.
• W2076656264 cites W1492893697 @default.
• W2076656264 cites W1531964529 @default.
• W2076656264 cites W1970377540 @default.
• W2076656264 cites W1975960976 @default.
• W2076656264 cites W1980451446 @default.
• W2076656264 cites W2011705265 @default.
• W2076656264 cites W2013066520 @default.
• W2076656264 cites W2014367403 @default.
• W2076656264 cites W2022292123 @default.
• W2076656264 cites W2023427658 @default.
• W2076656264 cites W2038409460 @default.
• W2076656264 cites W2038884210 @default.
• W2076656264 cites W2042670807 @default.
• W2076656264 cites W2051055358 @default.
• W2076656264 cites W2091666773 @default.
• W2076656264 cites W2100506877 @default.
• W2076656264 cites W2101789374 @default.
• W2076656264 cites W2120302849 @default.
• W2076656264 cites W2121409164 @default.
• W2076656264 cites W2126783165 @default.
• W2076656264 cites W2134831715 @default.
• W2076656264 cites W2143439281 @default.
• W2076656264 cites W2146778486 @default.
• W2076656264 cites W2152190583 @default.
• W2076656264 cites W2153061474 @default.
• W2076656264 cites W2158685508 @default.
• W2076656264 cites W2161151817 @default.
• W2076656264 cites W2162794726 @default.
• W2076656264 cites W2167188058 @default.
• W2076656264 cites W2169689529 @default.
• W2076656264 doi "https://doi.org/10.1007/s13277-013-1170-8" @default.
• W2076656264 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24014089" @default.
• W2076656264 hasPublicationYear "2013" @default.
• W2076656264 type Work @default.
• W2076656264 sameAs 2076656264 @default.
• W2076656264 citedByCount "25" @default.
• W2076656264 countsByYear W20766562642014 @default.
• W2076656264 countsByYear W20766562642015 @default.
• W2076656264 countsByYear W20766562642016 @default.
• W2076656264 countsByYear W20766562642017 @default.
• W2076656264 countsByYear W20766562642018 @default.
• W2076656264 countsByYear W20766562642019 @default.
• W2076656264 countsByYear W20766562642020 @default.
• W2076656264 countsByYear W20766562642021 @default.
• W2076656264 countsByYear W20766562642023 @default.
• W2076656264 crossrefType "journal-article" @default.
• W2076656264 hasAuthorship W2076656264A5021293751 @default.
• W2076656264 hasAuthorship W2076656264A5033919927 @default.
• W2076656264 hasAuthorship W2076656264A5047855118 @default.
• W2076656264 hasAuthorship W2076656264A5055174519 @default.
• W2076656264 hasAuthorship W2076656264A5068812571 @default.
• W2076656264 hasAuthorship W2076656264A5077322975 @default.
• W2076656264 hasConcept C109541995 @default.
• W2076656264 hasConcept C121608353 @default.
• W2076656264 hasConcept C126322002 @default.
• W2076656264 hasConcept C153911025 @default.
• W2076656264 hasConcept C185592680 @default.
• W2076656264 hasConcept C190283241 @default.
• W2076656264 hasConcept C202751555 @default.
• W2076656264 hasConcept C2776166826 @default.
• W2076656264 hasConcept C2778812593 @default.
• W2076656264 hasConcept C2779699572 @default.
• W2076656264 hasConcept C2780932548 @default.
• W2076656264 hasConcept C28328180 @default.
• W2076656264 hasConcept C2994423619 @default.
• W2076656264 hasConcept C502942594 @default.
• W2076656264 hasConcept C530470458 @default.
• W2076656264 hasConcept C553184892 @default.
• W2076656264 hasConcept C55493867 @default.
• W2076656264 hasConcept C71924100 @default.
• W2076656264 hasConcept C86554907 @default.
• W2076656264 hasConcept C86803240 @default.
• W2076656264 hasConcept C95444343 @default.
• W2076656264 hasConceptScore W2076656264C109541995 @default.
• W2076656264 hasConceptScore W2076656264C121608353 @default.
• W2076656264 hasConceptScore W2076656264C126322002 @default.
• W2076656264 hasConceptScore W2076656264C153911025 @default.
• W2076656264 hasConceptScore W2076656264C185592680 @default.
• W2076656264 hasConceptScore W2076656264C190283241 @default.
• W2076656264 hasConceptScore W2076656264C202751555 @default.
• W2076656264 hasConceptScore W2076656264C2776166826 @default.
• W2076656264 hasConceptScore W2076656264C2778812593 @default.
• W2076656264 hasConceptScore W2076656264C2779699572 @default.
• W2076656264 hasConceptScore W2076656264C2780932548 @default.
• W2076656264 hasConceptScore W2076656264C28328180 @default.
• W2076656264 hasConceptScore W2076656264C2994423619 @default.
• W2076656264 hasConceptScore W2076656264C502942594 @default.

• next